EndoSound

Executive Summary

EndoSound, based in Seattle, is a medical device company that has developed the EndoSound Vision System (EVS), a platform that converts any standard endoscope into a fully functional endoscopic ultrasound (EUS) system. By eliminating the need for dedicated, expensive EUS equipment, EndoSound aims to democratize access to advanced diagnostic and therapeutic EUS procedures, which are critical for conditions like pancreatic cancer and biliary diseases. The EVS system is designed to be more affordable and accessible, potentially expanding the installed base of EUS-capable centers from specialized tertiary hospitals to community hospitals and outpatient clinics. This addresses a significant market gap, as traditional EUS systems cost $200,000–$400,000, while the EVS offers a fraction of that cost using existing endoscopy infrastructure. EndoSound has received FDA 510(k) clearance for its EVS system and is focused on commercial launch and market adoption. The company’s strategy includes building a direct sales force and establishing key opinion leader (KOL) partnerships to drive adoption in the U.S. and eventually international markets. With the growing emphasis on early detection of gastrointestinal cancers and the increasing volume of endoscopic procedures, EndoSound is well-positioned to capture a share of the global EUS market, estimated at over $1 billion. However, the company faces competition from established EUS players like Olympus and Fujifilm, as well as the need to demonstrate superior clinical outcomes and cost-effectiveness to drive widespread adoption. Overall, EndoSound presents a compelling opportunity in the medical device space, with a clear value proposition and a sizable addressable market.

Upcoming Catalysts (preview)

• Q3 2026Commercial launch and first major hospital installations70% success
• Q4 2026Publication of pivotal clinical data comparing EVS to traditional EUS80% success
• TBDStrategic partnership or distribution agreement with a major endoscopy manufacturer50% success